• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Recent Generic Launches

Article

Several new generics have launched in the United States, including for the migraine therapy Zomig, the anticancer therapy Doxil, and an anti-inflammatory used to treat respiratory conditions associated with COVID-19.

Padagis Launches Generics of Zomig, Doxil

Padagis has launched a generic version of Zomig (zolmitriptan) Nasal Spray, which is used to treat adults and adolescents with migraine headaches with or without aura. The company has also launched a generic version of the anticancer agent Doxil (doxorubicin liposome injection) through its partnership with Ayana Pharma. Doxil is an anthracycline topoisomerase inhibitor that is used to treat patients with ovarian cancer, AIDS-related Kaposi’s sarcoma and multiple myeloma.

These are the company’s first launches since it separated from Perrigo in July 2021.

Amneal Launches Generic of Decadron

Amneal Pharmaceuticals has launched a generic version of Decadron, an anti-inflammatory glucocorticoid steroid used to treat several medical conditions, including respiratory complications associated with COVID-19.

Additionally the FDA has approved Amneal Pharmaceuticals’ abbreviated new drug application for difluprednate ophthalmic emulsion a generic version of Durezol and is used in the treatment of inflammation and pain associated with ocular surgery.

Endo Launches Generic of Miacalcin for Osteoporosis

Endo International’s Par Sterile Products business has begun shipping calcitonin salmon injection, a generic of Viatris’ Miacalcin, for the treatment of patients with hypercalcemic emergencies. It is also used for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause and to treat symptomatic Paget’s disease of bone.

It is offered in multi-dose vials (2 mL), and is manufactured in a U.S. facility in Rochester, Michigan.

Dr. Reddy’s Launches Generic of Akovaz

Dr. Reddy’s has launched Ephedrine Sulfate Injection 50 mg/mL, a therapeutic equivalent generic version of Exela Pharma’s Akovaz, which treats low blood pressure.

The product, which is a clear, colorless, sterile solution for intravenous injection and supplied as a 1 mL fill in a 2 mL clear glass single-dose vial with purple flip-off cap.

Related Content
© 2024 MJH Life Sciences

All rights reserved.